Business
Jaguar Health Reports 2019 Financial Results and Business Updates
Mytesi® net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018Reminder: Company to host investor call Monday, April 6 at 8:30 a.m.
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Mytesi® net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018Reminder: Company to host investor call Monday, April 6 at 8:30 a.m. EasternSAN FRANCISCO, CA / ACCESSWIRE / April 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today reported consolidated financial results for the year ended December 31, 2019 and provided business updates.\"We are very pleased to see strong Mytesi® (crofelemer) sales growth in 2019 over 2018,\" Lisa Conte, Jaguar's president and CEO, commented. \"Looking forward, we believe 2020 has the potential to be a transformative year for the Company. Our core goals for the year include forging a regional, ex-US business development deal to bring in non-dilutive dollars to support efforts to move key potential Mytesi pipeline indications into development, commercialization, and access outside the U.S., and completing the roll-out of our new, recently announced patient support program for Mytesi. Subject to additional financing, we are also planning to initiate three clinical trials in the second half of 2020 - a pivotal trial for the indication of prevention and treatment of cancer therapy-related diarrhea (CTD) in adult cancer patients, and two studies for the rare pediatric disease indications of congenital diarrheal disease and short bowel syndrome. For the adult CTD study, we've been in active discussions with the FDA, and in meetings with key opinion leaders, and have received their input on the clinical trial and statistical analysis plan. We are revising the clinical protocol to accommodate their input and preparing the requisite documents including the statistical analysis plan, the informed consent and other requirements to initiate this pivotal adult CTD trial under a new IND. The principal investigator is at a major cancer institution in the US. Finally, at a time when the world is grappling with a pandemic, we are pleased to announce that our wholly owned subsidiary, Napo Pharmaceuticals, will receive additional preclinical services from the National Institute of Allergy and Infectious Diseases (\"NIAID\") to support development of lechlemer, Napo's second generation, plant-based anti-secretory drug candidate for treatment of diarrhea associated with the enduring scourge of cholera. Under NIAID's suite of preclinical services, NIAID-funded co...